The fundraising was co-led by Radical Ventures, which specialises in AI software companies, and European healthcare venture firm Sofinnova Partners. Other investors include Jeff Dean, Google’s chief ...

Drug discovery is a costly and time-intensive process, with binding free energy calculations between the potential drug ...

Latent Labs has raised $50 million of new funding as it commercialises its GenAI technology for designing new proteins for drug discovery and development ...

His team harnesses advanced computational technologies, including AI, with the aim of enhancing the discovery, design, optimization and synthesis of small molecules to be developed into innovative ...

A novel geometric deep learning framework designs ligand-specific protein binders, enhancing therapeutic potential in cell therapies and synthetic biology.

Bind Research launched to transform disordered proteins into effective drug targetsUK’s first not-for-profit Focused Research Organisation ...

His team is now relying on a different computational chemistry technique ... new polymers or materials" that might be used in drug design or in semiconductor devices. The examination of heavier ...

Dr Alan D. Roth, CEO of Oxford Drug Design, highlighted the significance of their achievement. “This new milestone is a testament to the accuracy and reliability of our computational platform, SynthAI ...